News

Ligand Pharmaceuticals Plans Q2 Financial Results Conference Call

Ligand Pharmaceuticals Plans Q2 Financial Results Conference Call

Ligand Pharmaceuticals to Announce Q2 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has made an exciting announcement regarding its upcoming financial results. The company is set to report its second-quarter financial results soon, with the specific date confirmed for August 7, 2025.

Conference Call Details

As part of this announcement, Ligand will host a conference call to discuss the financial results and provide a broader update on its business activities. The call is scheduled to begin at 8:30 a.m. ET on the date of the financial report.

How to Join the Call

Investors and analysts can participate in the conference call by dialing either of the following numbers:

  • (800) 715-9871 for U.S. and Canada callers
  • (646) 307-1963 for international participants

For convenience, those joining the call will need to use Conference ID number 3661098.

Webcast Availability

Additionally, the conference call will be accessible via a live webcast. This will allow participants to listen online, enhancing accessibility for all interested parties. The recorded version will also be available later for those who cannot join the live session.

A Glimpse into Ligand Pharmaceuticals

Ligand Pharmaceuticals is a prominent biopharmaceutical company dedicated to fostering scientific progress. The company has made a name for itself in the industry by actively supporting the clinical development of a range of high-value medicines. To achieve this, Ligand employs a business model that provides both financing and licensing of its groundbreaking technologies.

Business Model Insights

Ligand’s operational strategy focuses on generating shareholder value through a diverse portfolio of revenue streams derived from biotechnology and pharmaceuticals. By maintaining a low corporate cost structure, Ligand aims to give investors a unique opportunity to engage with the biotechnology sector's promising future successfully. The company's approach includes funding mid- to late-stage drug development projects, acquiring royalty rights in emerging biopharmaceutical products, and licensing their proprietary technologies to enhance efficient drug discovery processes.

Strategic Partnerships

To further bolstering its revenue, Ligand collaborates with leading pharmaceutical companies, maximizing their strengths in late-stage development, regulatory management, and commercialization. This collaborative approach contributes significantly to the company’s ongoing success.

Technological Innovations by Ligand

Ligand leverages two innovative platform technologies that are core to its operations: Captisol® and NITRICIL™. The Captisol® technology is a chemically modified cyclodextrin that enhances drug stability and solubility, whereas NITRICIL™ offers adjustable drug release profiles, allowing for a tailored approach to various medical conditions.

Notable Partnerships

The company's significant partnerships include collaborations with top-tier firms such as Amgen, Merck, and Pfizer, which amplify its capacity to innovate and expand its product offerings. These alliances are integral in ensuring Ligand remains at the forefront of pharmaceutical advancements.

Staying Informed with Ligand Pharmaceuticals

Investors are encouraged to keep abreast of Ligand’s developments through their investor relations website. Furthermore, Ligand actively discloses important non-public information via this platform, aligning with the regulatory requirements to keep the investment community informed.

Connect with Ligand Pharmaceuticals

For any inquiries, investors can reach out to the company directly. The contact details are as follows:

Investors:
Melanie Herman
Email: investors@ligand.com
Phone: (858) 550-7761

Frequently Asked Questions

When will Ligand report its Q2 financial results?

Ligand is scheduled to report its Q2 financial results on August 7, 2025.

How can I participate in the Q2 results conference call?

You can join the conference call by calling (800) 715-9871 for U.S. participants or (646) 307-1963 for international participants.

Will there be a webcast for the conference call?

Yes, a live webcast will be available for those who wish to join online.

What technologies does Ligand Pharmaceuticals specialize in?

Ligand focuses on Captisol® and NITRICIL™ technologies to enhance drug development and delivery.

Who can I contact for more information about Ligand?

You can reach out to Melanie Herman at investors@ligand.com for investor inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 72

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 117

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 86

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 25

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Why Insurance Must Change as Family Assets Keep Growing

Updated Category News Views 32

A policy bought in the starter-home years can turn stale quietly while everything around it gets bigger, pricier and more complicated. That is the uncomfortable little truth behind Daniel C. DiCocco's discussion in HelloNation: families often treat insurance as a box checked long ago, even as they add property, savings, debt, children and fresh responsibilities. Static...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating Earnings: Barfresh Food Group's Upcoming Report

Updated Category News Views 61

Anticipating Earnings: Barfresh Food Group's Upcoming Report Barfresh Food Group (NASDAQ: BRFH) is on the brink of releasing its quarterly earnings. Investors are keenly awaiting the announcement, scheduled for Thursday. As the date approaches, it is crucial to analyze the expectations and historical performance of the company. The consensus among analysts is that...

Continue Reading
Meta's Smart Glasses: AI Performance Lags Behind ChatGPT's

Updated Category News Views 563

Meta's AI Tools Tested Against ChatGPT Recently, Gene Munster from Deepwater Asset Management conducted a head-to-head comparison of Meta Platforms Inc.'s AI capabilities on its smart glasses and the performance of OpenAI's ChatGPT. His findings highlighted significant gaps between the two AI systems. ChatGPT Outshines Meta AI in Tests During the evaluation, Munster...

Continue Reading
Tractor Supply Company Expands Offerings with Allivet Acquisition

Updated Category News Views 79

Tractor Supply Company to Acquire Allivet Tractor Supply Company (NASDAQ: TSCO), the top retailer for rural lifestyle in the U.S., has made an exciting announcement regarding its latest acquisition. The company has signed a definitive agreement to acquire Allivet, an esteemed private online pharmacy specializing in pet and animal health. This strategic move aims to...

Continue Reading
20+ Companies Break Ground in Urticaria Treatment Innovations

Updated Category News Views 236

Overview of Urticaria Treatment Innovations Urticaria, commonly known as hives, is a skin condition characterized by raised, itchy welts that can vary in size and location. The increasing prevalence of urticaria has spurred significant growth in treatment options, with various companies leading clinical trials dedicated to developing new therapies. Factors contributing to...

Continue Reading
Alphabet's Unique AI Strategy: A Competitive Edge Over Rivals

Updated Category News Views 241

Alphabet's AI Transformation and Competitive Advantage Alphabet Inc. (NASDAQ: GOOGL), a leader in technology innovation, is transforming its approach to artificial intelligence. The company, trading at $319.08 per share and boasting a market capitalization of $3.79 trillion, is narrowing the valuation gap with notable competitors. Its advancements in Tensor Processing...

Continue Reading